Navigation Links
Archimedes Pharma Announces Successful Proof-of-Concept Results on Two Intranasal Development Projects
Date:2/26/2009

READING, England, February 26 /PRNewswire/ --

- Intranasal Apomorphine for the Treatment of Motor Fluctuations in Advanced Parkinson's Disease

- Intranasal Diazepam for the Treatment of Acute Repetitive Seizures in Epilepsy

- Phase II Trials on Both Projects to be Initiated During 2009

Archimedes Pharma Limited, the pan-European specialty pharmaceutical company, today announces positive headline data from its recently completed proof-of-concept trials for two of its intranasal (IN) development projects. Both the IN Apomorphine and IN Diazepam Phase I studies showed high bioavailability, positive pharmacokinetics and good tolerability and confirmed that each candidate has the potential to replace existing formulations in high value markets. The agents are being developed for the treatment of motor fluctuations or "off episodes" in Parkinson's disease and Acute Repetitive Seizures ("ARS") in refractory epilepsy patients respectively.

Richard de Souza, CEO of Archimedes, said: "Both these trials have generated exciting results, highlighting the quality of our development capabilities and providing further validation of our business model. We look forward to driving our in-house development projects through to commercialization to provide an ongoing stream of novel products to our rapidly growing pan-European commercial organisation in therapeutic areas in which we already have an established presence. The strength of this strategy is exemplified by our lead development project, NasalFent(R), an intranasal fentanyl spray that has recently shown a best-in class profile for breakthrough cancer pain in our Phase III programme and the regulatory filings for which will begin in the first half of 2009."

Archimedes' IN Apomorphine and IN Diazepam have been developed by applying the world class drug delivery expertise of its subsidiary Archimedes Development lim
'/>"/>

SOURCE Archimedes Pharma Limited
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Adlyfe Strikes Translational Medicine Partnership With Wyeth Pharmaceuticals for Alzheimers Biomarker Assay
2. MAP Pharmaceuticals Announces Phase 3 Study of Unit Dose Budesonide in Children With Asthma Did Not Meet Primary Endpoints
3. AstraZenecas Partner, MAP Pharmaceuticals, Announces Phase 3 Study of Unit Dose Budesonide in Children with Asthma Did Not Meet Primary Endpoints
4. Cordex Pharma Announces Strategic Master Services Equity Agreement With Cato BioVentures
5. Shareholder Class Action Filed Against Rigel Pharmaceuticals, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP
6. Pharmacyclics, Inc. Announces Closing of a Private Financing With the Principals of Pacific Biopharma Group, Ltd.
7. Access Licenses ProLindac(TM) and MuGard(TM) to JCOM Ltd, an Affiliate of DONG-A Pharmaceuticals in Korea
8. ViroPharma Announces Discontinuation of Maribavir Phase 3 Study in Liver Transplant Patients
9. Inspiration Biopharmaceuticals, Inc. Initiates Phase 1 Clinical Trial of IB1001 for the Treatment of Hemophilia B
10. Endo Pharmaceuticals Announces Research Collaborations to Develop Novel Pain Treatments and Discover Potential Cancer Treatments
11. Sequoia Pharmaceuticals Presents Proof of Clinical Concept of SPI-452, a Novel Pharmacokinetic Enhancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... BUFFALO, N.Y. , May 4, 2015 /PRNewswire/ ... Stephanie Englert , PharmD, has completed preliminary analysis ... Disorder and Schizophrenia. Resources from Clinical Support Services, ... Medication Reviews (CMR) with patients currently taking psychiatric ... events. The research found that 93% of patients ...
(Date:5/4/2015)... 4, 2015 MEI Pharma, Inc. (Nasdaq: ... the clinical development of novel therapies for cancer, ... of the Company,s investigational drug candidate ME-344 in ... combined with a tyrosine-kinase inhibitor (TKI). In addition, ... a potent inhibitor of mitochondrial oxidative phosphorylation (OXPHOS) ...
(Date:5/4/2015)... , May 4, 2015  Geneia, a company ... technology solutions to improve healthcare efficiencies, today announced ... Rehabilitation Center (BNRC) use Geneia,s advanced analytics ... improve the quality and lower the cost of ... clinical, outcomes, claims and utilization data from multiple ...
Breaking Medicine Technology:Clinical Support Services, Inc. Verifies That Increased Availability of MTM Services Facilitates Identification of Adverse Drug Effects in Psychiatric Patients 2Clinical Support Services, Inc. Verifies That Increased Availability of MTM Services Facilitates Identification of Adverse Drug Effects in Psychiatric Patients 3MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 2MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 3MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 4MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 5Geneia Launches First-of-its-Kind Partnership to Use Advanced Analytics to Improve the Quality and Cost of Care for Skilled Nursing and Rehabilitation Patients 2Geneia Launches First-of-its-Kind Partnership to Use Advanced Analytics to Improve the Quality and Cost of Care for Skilled Nursing and Rehabilitation Patients 3
... Mylan Inc. (Nasdaq: www.mylan.com . ... release includes statements that constitute "forward-looking statements." These statements ... the Private Securities Litigation Reform Act of 1995. Because ... results may differ materially from those expressed or implied ...
... 6 Endo Pharmaceuticals (Nasdaq: ENDP ) today ... Specialty Pharmaceuticals Conference on Thursday, August 12, 2010 , at 8:00 ... Endo, will review the company,s products and development programs. , ... The presentation will be webcast live and can ...
Cached Medicine Technology:Endo to Present at the Bank of America Merrill Lynch 2010 Specialty Pharmaceuticals Conference 2
(Date:5/4/2015)... (PRWEB) May 04, 2015 Malibu ... oral antiseptic breath spray. KissSafe™ is the first ... a safer experience while adding fresh breath appeal. ... and effectively kills germs in the mouth and ... also contains ingredients that possess additional wellness benefits. ...
(Date:5/4/2015)... May 04, 2015 Milton Hershey School® ... 2015 Alumnus of the Year, recognizing his commitment to ... philanthropy he sets for MHS students. , “Dr. Graves ... happen when children are provided a top-notch education, a ... their passions,” said Pete Gurt ’85, president of MHS. ...
(Date:5/4/2015)... Johnson & Wales University (JWU) held a groundbreaking ceremony ... on Wednesday, April 22. , Johnson & Wales becomes the ... the re-alignment of Interstate-195. JWU’s new academic building, which will ... in Providence, is scheduled to be completed in July 2016. ... university purchased in 2012. , “It has long been our ...
(Date:5/4/2015)... The opportunity for children to dream of a ... forces behind The Fairy Godmother Next Door, a new children’s ... Stark. , The inspiration for the enchanting story of a ... Stark’s desire to be a fairy godmother. , “My wish ... my neighbors’ children since they were born. We discuss fairies ...
(Date:5/4/2015)... Now in its seventh year, the IPC ... made outstanding contributions to the company, to their facilities ... and post-acute care settings. The five award categories are: ... Year, Advanced Practice Clinician of the Year, Newcomer Provider ... Recipients are selected by IPC’s senior management team. , ...
Breaking Medicine News(10 mins):Health News:80 Million Germs from Kissing - Introducing KissSafe™ 2Health News:Milton Hershey School Names 2015 Alumnus of the Year 2Health News:Johnson & Wales University “Breaks Ground” On New $40 Million Engineering and Science Academic Center 2Health News:Johnson & Wales University “Breaks Ground” On New $40 Million Engineering and Science Academic Center 3Health News:Introducing New Children’s Book The Fairy Godmother Next Door 2Health News:IPC Healthcare Announces Clinicians of the Year 2Health News:IPC Healthcare Announces Clinicians of the Year 3
... Increased 15%; Online Ad Revenue Increased 21%WebMD Achieves ... and 1.3 Billion Quarterly Page ViewsNEW YORK, Feb. ... WBMD ) today announced financial results for the ... results confirm WebMD,s market leadership in a challenging ...
... Feb. 19 Covance Inc. (NYSE: CVD ) ... D., to its Board of Directors. Dr. Sheares is former ... of Reliant Pharmaceuticals, Inc., a pharmaceutical company that marketed a ... was president of the U.S. Human Health division of Merck ...
... prove cause and effect, researcher says , , THURSDAY, Feb. ... fast-food joints could increase your risk for stroke by ... restaurants are less plentiful, a new study suggests. , ... known, though, said study author Dr. Lewis B. Morgenstern, ...
... Netherlands, Feb. 19 A BioPharma Pavilion at CPhI ... P-MEC Japan will be ... Japan ,s leading pharma services events by UBM International Media. ... completed by the contract services event ICSE Japan -- will be ...
... statins, used by millions of Americans to treat ... according to researchers at Texas Health Presbyterian Hospital ... the influence of statin drugs," appears in the ... make quicker, more accurate diagnoses of suspected thyroid ...
... monitoring can keep problem from advancing, experts say , , THURSDAY, ... levels causes poorer brain function in people with type 2 ... aged 55 and older at 52 sites in Canada and ... a larger study on cardiovascular risk in diabetes, underwent cognitive ...
Cached Medicine News:Health News:WebMD Announces Fourth Quarter Financial Results 2Health News:WebMD Announces Fourth Quarter Financial Results 3Health News:WebMD Announces Fourth Quarter Financial Results 4Health News:WebMD Announces Fourth Quarter Financial Results 5Health News:WebMD Announces Fourth Quarter Financial Results 6Health News:WebMD Announces Fourth Quarter Financial Results 7Health News:WebMD Announces Fourth Quarter Financial Results 8Health News:WebMD Announces Fourth Quarter Financial Results 9Health News:WebMD Announces Fourth Quarter Financial Results 10Health News:WebMD Announces Fourth Quarter Financial Results 11Health News:WebMD Announces Fourth Quarter Financial Results 12Health News:WebMD Announces Fourth Quarter Financial Results 13Health News:WebMD Announces Fourth Quarter Financial Results 14Health News:WebMD Announces Fourth Quarter Financial Results 15Health News:WebMD Announces Fourth Quarter Financial Results 16Health News:WebMD Announces Fourth Quarter Financial Results 17Health News:WebMD Announces Fourth Quarter Financial Results 18Health News:WebMD Announces Fourth Quarter Financial Results 19Health News:Covance Elects Bradley T. Sheares to Company's Board of Directors 2Health News:More Fast-Food Joints in Neighborhoods Mean More Strokes 2Health News:New Features for 2009 Japan Events 2Health News:New Features for 2009 Japan Events 3Health News:Dallas Scientists Discover Statins May Falsely Indicate Thyroid Problems 2Health News:Out-of-Control Blood Sugar May Affect Memory 2
400 Series Monopolar Foot Activated Forceps...
Dissecting Forceps, straight, with RF-cable, 7" (18 cm). For use with all electrosurgical generators with standard three-prong sockets....
Extended blade - 25/box....
... In the way it implements the ... 510 Meta system is unmatched. It allows ... compromising resolution and efficiency. Unprecedented flexibility for ... functions that guarantee fast and efficient structural ...
Medicine Products: